Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • Nikkei

    40,369.44
    +201.37 (+0.50%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Bitcoin USD

    70,087.38
    -206.42 (-0.29%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • FTSE Bursa Malaysia

    1,540.55
    +9.95 (+0.65%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Merck beats forecasts, newer drugs offset impact of generics

A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009. REUTERS/Jeff Zelevansky

(Reuters) - Merck & Co (MRK.N) reported better-than-expected quarterly results on Tuesday, with sales of newer drugs helping to offset the impact of generic competition on the sales of other drugs.

The No. 2 U.S. drugmaker earned $2.03 billion ( 1.19 billion pounds), or 68 cents per share, in the second quarter. That compared with $906 million, or 30 cents per share, in the year-earlier period, when Merck took charges for acquisitions and restructuring.

Excluding special items, Merck earned 85 cents per share. Analysts, on average, were expecting 81 cents per share, according to Thomson Reuters I/B/E/S.

Global revenue slipped 1 percent to $10.93 billion, but exceeded Wall Street expectations of $10.6 billion.

Merck said it expects full-year earnings of $3.43 to $3.53 per share. In April, it had predicted $3.35 to $3.53.

(Reporting by Ransdell Pierson; Editing by Bernadette Baum)